Pharma-Bio Serv, Inc. (PBSV) stock intrinsic value fair value estimate & owner earnings analysis

THE BUSINESS. Pharma-Bio Serv is a small consulting firm based in Dorado, Puerto Rico. It sells the time of engineers and life-science specialists who help drug, biotech, medical-device and similar manufacturers meet FDA and international regulatory rules: validation, quality compliance and moving production processes from one site to another. Its fiscal year ends October 31. In fiscal 2025, 51.5% of revenue came from Puerto Rico, 29.1% from the mainland United States and 19.2% from Europe, where it works through a Spanish subsidiary. Three customer groups made up 43.5% of revenue. WHAT CHANGED. Revenue fell from $17.0 million in fiscal 2023 to $9.5 million in fiscal 2024 and $9.0 million in fiscal 2025. High-margin European projects ended in fiscal 2023, and project work in Puerto Rico and the United States also declined. The company lost $1.29 million from operations in fiscal 2024 and $0.64 million in fiscal 2025. In the first half of fiscal 2026 revenue was $5.0 million, up 2% on the prior year, and operations earned $50,000. Only the second quarter was profitable, at $145,000. The headquarters lease expired on December 31, 2025 and the company now works virtually, saving about $170,000 a year in rent. WHERE THE VALUE IS. Most of what this company is worth is surplus cash. At April 30, 2026 it held $1.79 million in cash and $6.68 million in short-term US Treasury securities, $8.47 million in total. It reports no other investments and no debt. Against that it owed $1.05 million of short-term bills: $0.98 million of payables and accrued expenses and $0.07 million of income taxes. Customers owed it $2.72 million. Six months earlier, at October 31, 2025, cash and Treasuries were $10.85 million; the drop is almost exactly the $1.72 million dividend paid in March 2026 plus about $0.66 million of taxes, which included the last installment of the one-time tax on overseas earnings from the 2017 US tax law. HOW WE COUNTED. We treat this as a small consulting business sitting on a pile of surplus cash that the board is paying out, and we value the two parts separately. The payout is well established: the company has paid $0.075 per share, about $1.72 million, in every fiscal year from 2020 through 2026, and twice in fiscal 2022, returning about $13.3 million in all, far more than the business earned over that time. We set aside cash equal to the $1.05 million of bills owed as the working cash the business needs, which leaves about $7.43 million, or $0.32 per share, of surplus. We value that surplus as the dividends it funds: at the current rate, and earning roughly 4% on the unpaid balance (about what the Treasuries earned in fiscal 2025), it lasts about four and a half years, and those payments are worth about $7.12 million, or $0.31 per share, today. The consulting business is valued on its own cash earnings, leaving out the interest on the cash, so no dollar is counted twice. There is no debt, so nothing is subtracted. Office rent is counted as a real cash cost in past years. A $5.25 million receivable from a customer, Romark, written off in fiscal 2021 for work done in 2019 and 2020, is counted as a real loss, not as an accounting charge to ignore. The 2017 overseas-earnings tax, about $2.7 million, is charged once, in fiscal 2018, when it arose. We measure the consulting business from fiscal 2024 onward, because the roughly $9 million revenue company of today is not the $17 million company of fiscal 2023. Leaving out interest and other non-operating income, the consulting business lost about $1.45 million in fiscal 2024 and $0.59 million in fiscal 2025, an improvement of about $0.86 million. The last half-year was close to break-even. BEAR CASE, $0.17 PER SHARE. The consulting business keeps losing about $0.85 million a year, the fiscal 2024 to 2025 average less the rent saving, for four years. Management then cuts costs to break even, as its reductions in 2025 and 2026 show it is willing to do. On top of that, one customer fails to pay about $0.4 million, a smaller repeat of the Romark loss that is possible because three customer groups make up 43.5% of revenue. Those losses would use up about $3.8 million of the surplus, leaving roughly $3.6 million, or $0.16 per share, to pay out. Counted in today's money, the dividends less those losses come to $0.17 per share. That is a little more than the $0.16 per share left to pay out, because the losses are spread over four years and so weigh less in today's money than their face amount, while most of the dividends are paid sooner. BASE CASE, $0.33 PER SHARE. The consulting business loses about $0.2 million next year, breaks even the year after, then earns about $0.1 million a year through year 10, fading to nothing by year 14 because nothing in the filings shows it earning more on today's revenue base. The first year assumes a $0.39 million improvement on fiscal 2025, less than the $0.86 million improvement achieved in fiscal 2025 and supported by the rent saving; we start below the first-half 2026 pace (about $0.15 million a year) because only one of the last two quarters was profitable. The consulting business adds about $0.46 million, or $0.02 per share, to the $0.31 per share of dividends. BULL CASE, $0.51 PER SHARE. The first-half 2026 improvement holds, giving about $0.15 million of owner earnings next year. Europe keeps growing (it added $1.2 million of revenue in fiscal 2025), recent margin gains stick (gross margin rose 5.8 points in fiscal 2025), and overhead stays lower. The consulting business reaches about $0.6 million a year of owner earnings by year 3, still below the roughly $0.8 million it earned before interest in fiscal 2023 on $17.0 million of revenue. Those earnings hold through year 10 and fade to nothing over the following five years. The consulting business adds about $4.55 million, or $0.20 per share, to the dividends. WHAT WE LEFT OUT. In November 2023 a Puerto Rico court ordered Romark to pay the company $6.7 million. The company says it has found no Romark assets to collect from, and other creditors are also pursuing claims. We give this judgment no value. The Puerto Rico tax grant that set a 4% income tax rate on local services expired on October 31, 2024; a 15-year renewal has been requested and is still pending, while a separate grant covering services to customers outside Puerto Rico runs to December 30, 2039. This matters only if the business becomes solidly profitable, so a denial would slightly lower the bull case. The filings describe new US tariffs only as a risk to customer demand, and there is no evidence yet of more work from drug makers moving production back to the United States, so we did not include any. When the business is wound down, if ever, the working cash and net receivables left in it would also come back to shareholders; we do not count them because nothing in the filings points to that. WHAT WOULD MAKE THIS WRONG. The consulting business could lose cash faster or for longer than the bear case assumes. A top customer could leave. The board could stop the dividend and keep the cash, or spend it on an acquisition, instead of paying it out as it has for seven years. Our earlier estimate put the cash at about $9.1 million and added all of it at face value; the company actually held $8.47 million at April 30, 2026, and we now set aside the working cash the business needs and value the rest as the dividends it funds over time, which lowers each case by $0.08 to $0.09 per share. Our view of the consulting business itself is unchanged. The margin-of-safety price of $0.15 is below the bear case: from that price the bear case implies dividends slightly exceeding the price, and the current dividend alone equals half that price each year while it lasts.